In this trial, patients with CBF-AML [17], AML with mutated NPM1 [18], and AML with FLT3 internal tandem duplication (ITD) [19] were excluded due to competitive trials that were active during the same time resulting in a selection of patients with more high-risk disease features. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.